Global Hyperimmune Serum Market
Global Hyperimmune Serum Market

Hyperimmune Serum Comprehensive Study by Application (Hepatitis B, Rabies, Tetanus, Others), End-users (Government Institutions, Private Sector, Other) Players and Region - Global Market Outlook to 2026

Hyperimmune Serum Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 224 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Hyperimmune Serum Market?

The hyperimmune serum is blood plasma containing high amounts of an antibody, which is about 150 times more potent than the convalescent plasm. This can be an important therapeutic alternative against SARS-CoV-2 for people who infected with the coronavirus. The factors such as the Increased Number of COVID-19 Cases Worldwide Leads to Demand for Alternative Treatments and Increased Prevalence of Infectious Diseases are the key drivers for the global Hyperimmune Serum market. In addition, Increased Investments in Health Care Sector also fueling market growth. However, Side Effects Associated with Hyperimmune Serum may hamper the market growth.

The market study is being classified, by Application (Hepatitis B, Rabies, Tetanus and Others) and major geographies with country level break-up.

CSL Behring (United States), Shanghai RAAS blood products Co., Ltd. (China), Grifols, S.A. (Spain), Kedrion (Italy), China Biologic Products, Inc (China), Biotest (Germany), China National Biotec Group Company (China), Hualan Biological Engineering Inc. (China), Kamada Ltd. (Israel), Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd. (China) and ADMA Biologics, Inc. (United States) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Chinese Players will contribute to the maximum growth of Global Hyperimmune Serum market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Hyperimmune Serum market by Type, Application and Region.

On the basis of geography, the market of Hyperimmune Serum has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Number of COVID-19 Cases Worldwide Leads to Demand for Alternative Treatments
  • Increased Prevalence of Infectious Diseases

Market Trend
  • Increased Investments in Health Care Sector

Restraints
  • Side Effects Associated with Hyperimmune Serum

Opportunities
  • Increased Research and Development Activities
  • Growth in the Healthcare Industry Worldwide

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Manufacturers, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hepatitis B
  • Rabies
  • Tetanus
  • Others
By End-users
  • Government Institutions
  • Private Sector
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Number of COVID-19 Cases Worldwide Leads to Demand for Alternative Treatments
      • 3.2.2. Increased Prevalence of Infectious Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Investments in Health Care Sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hyperimmune Serum, by Application, End-users and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hyperimmune Serum (Value)
      • 5.2.1. Global Hyperimmune Serum by: Application (Value)
        • 5.2.1.1. Hepatitis B
        • 5.2.1.2. Rabies
        • 5.2.1.3. Tetanus
        • 5.2.1.4. Others
      • 5.2.2. Global Hyperimmune Serum by: End-users (Value)
        • 5.2.2.1. Government Institutions
        • 5.2.2.2. Private Sector
        • 5.2.2.3. Other
      • 5.2.3. Global Hyperimmune Serum Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Hyperimmune Serum: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CSL Behring (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Shanghai RAAS blood products Co., Ltd. (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Grifols, S.A. (Spain)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Kedrion (Italy)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. China Biologic Products, Inc (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biotest (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. China National Biotec Group Company (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hualan Biological Engineering Inc. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Kamada Ltd. (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd. (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. ADMA Biologics, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Hyperimmune Serum Sale, by Application, End-users and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Hyperimmune Serum (Value)
      • 7.2.1. Global Hyperimmune Serum by: Application (Value)
        • 7.2.1.1. Hepatitis B
        • 7.2.1.2. Rabies
        • 7.2.1.3. Tetanus
        • 7.2.1.4. Others
      • 7.2.2. Global Hyperimmune Serum by: End-users (Value)
        • 7.2.2.1. Government Institutions
        • 7.2.2.2. Private Sector
        • 7.2.2.3. Other
      • 7.2.3. Global Hyperimmune Serum Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hyperimmune Serum: by Application(USD Million)
  • Table 2. Hyperimmune Serum Hepatitis B , by Region USD Million (2015-2020)
  • Table 3. Hyperimmune Serum Rabies , by Region USD Million (2015-2020)
  • Table 4. Hyperimmune Serum Tetanus , by Region USD Million (2015-2020)
  • Table 5. Hyperimmune Serum Others , by Region USD Million (2015-2020)
  • Table 6. Hyperimmune Serum: by End-users(USD Million)
  • Table 7. Hyperimmune Serum Government Institutions , by Region USD Million (2015-2020)
  • Table 8. Hyperimmune Serum Private Sector , by Region USD Million (2015-2020)
  • Table 9. Hyperimmune Serum Other , by Region USD Million (2015-2020)
  • Table 10. South America Hyperimmune Serum, by Country USD Million (2015-2020)
  • Table 11. South America Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 12. South America Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 13. Brazil Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 14. Brazil Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 15. Argentina Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 16. Argentina Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 17. Rest of South America Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 18. Rest of South America Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 19. Asia Pacific Hyperimmune Serum, by Country USD Million (2015-2020)
  • Table 20. Asia Pacific Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 21. Asia Pacific Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 22. China Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 23. China Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 24. Japan Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 25. Japan Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 26. India Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 27. India Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 28. South Korea Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 29. South Korea Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 30. Taiwan Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 31. Taiwan Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 32. Australia Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 33. Australia Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 34. Rest of Asia-Pacific Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 36. Europe Hyperimmune Serum, by Country USD Million (2015-2020)
  • Table 37. Europe Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 38. Europe Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 39. Germany Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 40. Germany Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 41. France Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 42. France Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 43. Italy Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 44. Italy Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 45. United Kingdom Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 46. United Kingdom Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 47. Netherlands Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 48. Netherlands Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 49. Rest of Europe Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 50. Rest of Europe Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 51. MEA Hyperimmune Serum, by Country USD Million (2015-2020)
  • Table 52. MEA Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 53. MEA Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 54. Middle East Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 55. Middle East Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 56. Africa Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 57. Africa Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 58. North America Hyperimmune Serum, by Country USD Million (2015-2020)
  • Table 59. North America Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 60. North America Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 61. United States Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 62. United States Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 63. Canada Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 64. Canada Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 65. Mexico Hyperimmune Serum, by Application USD Million (2015-2020)
  • Table 66. Mexico Hyperimmune Serum, by End-users USD Million (2015-2020)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Hyperimmune Serum: by Application(USD Million)
  • Table 79. Hyperimmune Serum Hepatitis B , by Region USD Million (2021-2026)
  • Table 80. Hyperimmune Serum Rabies , by Region USD Million (2021-2026)
  • Table 81. Hyperimmune Serum Tetanus , by Region USD Million (2021-2026)
  • Table 82. Hyperimmune Serum Others , by Region USD Million (2021-2026)
  • Table 83. Hyperimmune Serum: by End-users(USD Million)
  • Table 84. Hyperimmune Serum Government Institutions , by Region USD Million (2021-2026)
  • Table 85. Hyperimmune Serum Private Sector , by Region USD Million (2021-2026)
  • Table 86. Hyperimmune Serum Other , by Region USD Million (2021-2026)
  • Table 87. South America Hyperimmune Serum, by Country USD Million (2021-2026)
  • Table 88. South America Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 89. South America Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 90. Brazil Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 91. Brazil Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 92. Argentina Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 93. Argentina Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 94. Rest of South America Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 95. Rest of South America Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 96. Asia Pacific Hyperimmune Serum, by Country USD Million (2021-2026)
  • Table 97. Asia Pacific Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 98. Asia Pacific Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 99. China Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 100. China Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 101. Japan Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 102. Japan Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 103. India Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 104. India Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 105. South Korea Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 106. South Korea Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 107. Taiwan Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 108. Taiwan Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 109. Australia Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 110. Australia Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 111. Rest of Asia-Pacific Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 112. Rest of Asia-Pacific Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 113. Europe Hyperimmune Serum, by Country USD Million (2021-2026)
  • Table 114. Europe Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 115. Europe Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 116. Germany Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 117. Germany Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 118. France Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 119. France Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 120. Italy Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 121. Italy Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 122. United Kingdom Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 123. United Kingdom Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 124. Netherlands Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 125. Netherlands Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 126. Rest of Europe Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 127. Rest of Europe Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 128. MEA Hyperimmune Serum, by Country USD Million (2021-2026)
  • Table 129. MEA Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 130. MEA Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 131. Middle East Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 132. Middle East Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 133. Africa Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 134. Africa Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 135. North America Hyperimmune Serum, by Country USD Million (2021-2026)
  • Table 136. North America Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 137. North America Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 138. United States Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 139. United States Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 140. Canada Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 141. Canada Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 142. Mexico Hyperimmune Serum, by Application USD Million (2021-2026)
  • Table 143. Mexico Hyperimmune Serum, by End-users USD Million (2021-2026)
  • Table 144. Research Programs/Design for This Report
  • Table 145. Key Data Information from Secondary Sources
  • Table 146. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hyperimmune Serum: by Application USD Million (2015-2020)
  • Figure 5. Global Hyperimmune Serum: by End-users USD Million (2015-2020)
  • Figure 6. South America Hyperimmune Serum Share (%), by Country
  • Figure 7. Asia Pacific Hyperimmune Serum Share (%), by Country
  • Figure 8. Europe Hyperimmune Serum Share (%), by Country
  • Figure 9. MEA Hyperimmune Serum Share (%), by Country
  • Figure 10. North America Hyperimmune Serum Share (%), by Country
  • Figure 11. Global Hyperimmune Serum share by Players 2020 (%)
  • Figure 12. Global Hyperimmune Serum share by Players (Top 3) 2020(%)
  • Figure 13. Global Hyperimmune Serum share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. CSL Behring (United States) Revenue, Net Income and Gross profit
  • Figure 16. CSL Behring (United States) Revenue: by Geography 2020
  • Figure 17. Shanghai RAAS blood products Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 18. Shanghai RAAS blood products Co., Ltd. (China) Revenue: by Geography 2020
  • Figure 19. Grifols, S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 20. Grifols, S.A. (Spain) Revenue: by Geography 2020
  • Figure 21. Kedrion (Italy) Revenue, Net Income and Gross profit
  • Figure 22. Kedrion (Italy) Revenue: by Geography 2020
  • Figure 23. China Biologic Products, Inc (China) Revenue, Net Income and Gross profit
  • Figure 24. China Biologic Products, Inc (China) Revenue: by Geography 2020
  • Figure 25. Biotest (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Biotest (Germany) Revenue: by Geography 2020
  • Figure 27. China National Biotec Group Company (China) Revenue, Net Income and Gross profit
  • Figure 28. China National Biotec Group Company (China) Revenue: by Geography 2020
  • Figure 29. Hualan Biological Engineering Inc. (China) Revenue, Net Income and Gross profit
  • Figure 30. Hualan Biological Engineering Inc. (China) Revenue: by Geography 2020
  • Figure 31. Kamada Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Kamada Ltd. (Israel) Revenue: by Geography 2020
  • Figure 33. Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 34. Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd. (China) Revenue: by Geography 2020
  • Figure 35. ADMA Biologics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. ADMA Biologics, Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Global Hyperimmune Serum: by Application USD Million (2021-2026)
  • Figure 38. Global Hyperimmune Serum: by End-users USD Million (2021-2026)
  • Figure 39. South America Hyperimmune Serum Share (%), by Country
  • Figure 40. Asia Pacific Hyperimmune Serum Share (%), by Country
  • Figure 41. Europe Hyperimmune Serum Share (%), by Country
  • Figure 42. MEA Hyperimmune Serum Share (%), by Country
  • Figure 43. North America Hyperimmune Serum Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • CSL Behring (United States)
  • Shanghai RAAS blood products Co., Ltd. (China)
  • Grifols, S.A. (Spain)
  • Kedrion (Italy)
  • China Biologic Products, Inc (China)
  • Biotest (Germany)
  • China National Biotec Group Company (China)
  • Hualan Biological Engineering Inc. (China)
  • Kamada Ltd. (Israel)
  • Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd. (China)
  • ADMA Biologics, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation